HIGHLIGHTS
- Record revenues of A$28.8m for the year ended 30 June 2025 and in line with guidance
- Six consecutive half-years of growth in the USA with H2FY25 US sales up 25% on pcp
- Q4FY25 sales of A$8.4m the highest on record
Nova Eye Medical Limited (ASX: EYE) (Nova Eye or the Company) is pleased to report a record sales result for FY25.
Group revenue for FY25 reached A$28.8 million (US$18.4 million), up 21% (in constant currency) from FY24.
Key drivers include:
- US sales of US$14.2 million, up 25% with iTrack™ Advance delivering six consecutive half-years of revenue growth.
- H2FY25 sales A$15.7 million (US$10 million) up 46% on pcp (in constant currency) and in line with guidance
- Q4FY25 sales of A$8.4 million (US$5.4 million) were the highest on record
The record result underscores the continued adoption of iTrack™ Advance and growing global recognition of Nova Eye’s technology. Nova Eye expects revenue growth to continue in FY26.
Read ASX Announcement here: Record Revenues for FY25
Investor Webinar - Managing Director Tom Spurling will discuss Nova Eye Medical’s record sales results for the FY25 period.
- Date: Wednesday, 9 July 2025
- Time: 11.30am AEST
- Presenter: Tom Spurling, Nova Eye Medical Managing Director
- Registration Link: https://us02web.zoom.us/webinar/register/WN_IimrVT61QIOsfgfkG0ybPA
Participants will have the opportunity to submit questions before the webinar by emailing [email protected] or during the live Q&A session.
Read Investor Presentation here: Nova Eye Medical Limited (ASX:EYE) Investor Webinar Presentation
For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com
About us:
ABOUT NOVA EYE MEDICAL
Nova Eye Medical Limited is a medical technology company that develops, manufactures andsells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance a minimally invasive consumable glaucoma surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.
For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com
Contact details:
Company
Tom Spurling
Managing Director
+61 417 818 658
[email protected]
Investors
Mark Flynn
Investor Relations
+61 416 068 733
[email protected]
